Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 10;2(3):e100086.
doi: 10.1136/egastro-2024-100086. eCollection 2024 Sep.

Causal role of the gut microbiome in certain human diseases: a narrative review

Connor Prosty  1 , Khaled Katergi  2 , Jesse Papenburg  3 , Alexander Lawandi  4 , Todd C Lee  4   5 , Hao Shi  6 , Philip Burnham  6 , Lee Swem  6 , Bertrand Routy  7 , Cedric P Yansouni  4   8 , Matthew P Cheng  1   4   6
Affiliations
Review

Causal role of the gut microbiome in certain human diseases: a narrative review

Connor Prosty et al. eGastroenterology. .

Abstract

Composed of an elaborate ecosystem of bacteria, fungi, viruses and protozoa residing in the human digestive tract, the gut microbiome influences metabolism, immune modulation, bile acid homeostasis and host defence. Through observational and preclinical data, the gut microbiome has been implicated in the pathogenesis of a spectrum of chronic diseases ranging from psychiatric to gastrointestinal in nature. Until recently, the lack of unequivocal evidence supporting a causal link between gut microbiome and human health outcomes incited controversy regarding its significance. However, recent randomised controlled trial (RCT) evidence in conditions, such as Clostridioides difficile infection, cancer immunotherapy and ulcerative colitis, has supported a causal relationship and has underscored the potential of the microbiome as a therapeutic target. This review delineates the RCT evidence substantiating the potential for a causal relationship between the gut microbiome and human health outcomes, the seminal observational evidence that preceded these RCTs and the remaining knowledge gaps.

Keywords: Gastrointestinal Microbiome; Intestinal Microbiota; Ulcerative Colitis.

PubMed Disclaimer

Conflict of interest statement

JP reports grants from MedImmune, grants and personal fees from Merck and personal fees from AstraZeneca, all outside the submitted work. TCL has operating grants from the CIHR and receives salary support from the Fonds de Recherche du Québec—Santé outside of this work. HS is the cofounder and chief technical officer of Kanvas Biosciences and owns equity in the company. PB is the chief scientific officer of Kanvas Biosciences. LS is the chief development officer of Kanvas Biosciences. BR has received grant funding from Davolterra and Kanvas and honoraria from Merck, BMS and AstraZeneca and is the cofounder of Curebiota. CPY reports being on an independent data monitoring committee for Medicago. MPC reports operating grants from the Canadian Institutes of Health Research during the conduct of the study and salary support from the Fonds de Recherche du Québec—Santé, both unrelated to this work; personal fees from GEn1E Lifesciences and Nomic Bio as a member of the scientific advisory board; personal fees from AstraZeneca as a scientific consultant; research support from Cidara Therapeutics, Scynexis and Amplyx Pharmaceutics during the conduct of the study but outside the submitted work; is the cofounder of Kanvas Biosciences and owns equity in the company; and has pending patents, including: (1) methods for detecting tissue damage, graft-versus-host disease and infections using cell-free DNA profiling, (2) methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA pending and (3) rapid identification of antimicrobial resistance and other microbial phenotypes using highly multiplexed fluorescence in situ hybridisation. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Functions of the gut microbiome. Created with BioRender.com. SCFA, short chain fatty acids.
Figure 2
Figure 2. Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. C. difficile, Clostridioides difficile; RCT, randomised controlled trial.
See this image and copyright information in PMC

References

    1. Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14:e1002533. doi: 10.1371/journal.pbio.1002533. - DOI - PMC - PubMed
    1. Rinninella E, Raoul P, Cintoni M, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7:14. doi: 10.3390/microorganisms7010014. - DOI - PMC - PubMed
    1. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature New Biol. 2010;464:59–65. doi: 10.1038/nature08821. - DOI - PMC - PubMed
    1. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–4. doi: 10.1126/science.aad3503. - DOI - PubMed
    1. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016;375:2369–79. doi: 10.1056/NEJMra1600266. - DOI - PubMed

LinkOut - more resources